Background: Several studies demonstrated that glioblastoma multiforme progression and recurrence is linked to epigenetic regulatory mechanisms. Sirtuin 1 (SIRT1) plays an important role in glioma progression, invasion, and treatment response, and is a potential therapeutic target. The aim of this study is to test the feasibility of 2-[ 18 F]BzAHA for quantitative imaging of SIRT1 expression-activity and monitoring pharmacologic inhibition in a rat model of intracerebral glioma. Methods: Sprague Dawley rats bearing 9L (N=12) intracerebral gliomas were injected with 2-[ 18 F]BzAHA (300-500 µCi/animal i.v.) and dynamic PET imaging was performed for 60 minutes. Then, SIRT1 expression in 9L tumors (N=6) was studied by immunofluorescence microscopy (IFM). Two days later, rats with 9L gliomas were treated either with SIRT1 specific inhibitor EX-527 (5 mg/kg, i.p; N=3) or with HDACs class IIa specific inhibitor MC1568 (30 mg/kg, i.p.; N=3) and 30 minutes later were injected i.v. with 2-[ 18 F]BzAHA. PET/CT/(MR) images acquired after EX-527 and MC1568 treatments were co-registered with baseline images. Results: Standard uptake values (SUV) of 2-[ 18 F]BzAHA in 9L tumors measured at 20 min post radiotracer administration were 1.11±0.058 for SUV and had an tumor-to-brainstem SUV ratio of 2.73±0.141. IFM of 9L gliomas revealed heterogeneous upregulation of SIRT1, especially in hypoxic and perinecrotic regions. Significant reduction in 2-[ 18 F]BzAHA SUV and distribution volume in 9L tumors was observed after administration of EX-527, but not MC1568. Conclusions: Thus, PET/CT/(MR) with 2-[ 18 F]BzAHA can facilitate studies to elucidate the roles of SIRT1 in gliomagenesis and progression and to optimize therapeutic doses of novel SIRT1 inhibitors in gliomas.
Introduction
Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumors, comprising 53.8% of all malignant primary brain tumors, with the annual incidence of about 3 cases per 100,000 people per year and the mean survival time of just 15 months after diagnosis. 1 In the last decade, progress towards treatments with improved overall survival and prolonged time to progression has largely stalled. Therefore, research in molecular genetics of gliomas has come to the forefront for development of novel more effective therapies. Several studies demonstrated that GBM progression and recurrence is linked to epigenetic regulatory mechanisms including: mutations in IDH1/IDH2 genes, epigenetic modifying enzymes, histone deacetylases (HDACs), histone methyltransferases (HMTs), DNA methyltransferases (DNMT) and various DNA demethylases. 2 These epigenetic regulators contribute to malignant transformation and progression by influencing the spectrum and magnitude of gene expression, DNA repair, cell cycle, stability and function of non-histone proteins involved in glioma cell signaling and regulation of metabolism, apoptosis, and senescence. [3] [4] [5] In particular, HDACs cleave an acetyl moiety from the Ɛamino terminus of lysine residues on histone core and non-histone proteins. Amongst four classes of HDACs, class III HDACs are homologous to yeast Sir2 protein, known as "silent information regulators" or "sirtuins", and includes seven isotypes (SIRTs1-7). 6 SIRTs differ from other HDAC classes in that their catalytic activities are NAD + -dependent, whereas the other HDACs are Zn-dependent. Many SIRTs are involved in regulation of protein stability and functions outside of the nucleus and cleave other moieties aside from acetyl, such as malonyl, succinyl, glutaryl, lipoyl, palmitoyl, and others. 7 In particular, SIRT1 has been implicated in a variety of disease processes, including diabetes, cardiovascular disease, and neurodegeneration. 8 Also, SIRT1 is involved in the pathogenesis of multiple malignancies, including: hematologic, 9 oral, 10 pancreatic, 11 liver, 12 lung, 13 breast, 14 and brain. 15 In the nucleus, SIRT1 deacetylates several histone lysines, including H1K26, 16 H3K4, H3K9, and H4K16. 17 Deacetylated histone protein tails bind with Downloaded from https://academic.oup.com/noa/advance-article-abstract/doi/10.1093/noajnl/vdaa006/5707328 by guest on 02 February 2020 A c c e p t e d M a n u s c r i p t 5 higher affinity to adjacent DNA, hindering the binding of transcription complexes and effectively "silencing" gene expression. 18 Global loss of acH4K16 has been described as a hallmark of cancer in humans and associated with early stages of tumor formation. 19 
SIRT1
shuttles from the nucleus into the cytoplasm, 20,21 where it deacetylates and regulates the stability and function of several non-histone proteins, including: p53, p73, FOXO, E2F1, NF-κB, and others. 22-24 SIRT1 deacetylates and stabilizes HIF-1α, 25,26 thereby increasing expression of VEGF, GLUT1, and MMP2. 25 Increased SIRT1 expression within tumor cells promotes cell survival, proliferation, and angiogenesis in conditions of oxidative and metabolic stress through dysregulation of apoptotic pathways. [27] [28] [29] [30] [31] [32] [33] Genetic and pharmacologic inhibition of SIRT1 activity arrests tumor growth and restores proper apoptotic signaling. [33] [34] [35] [36] SIRT1 is required for oncogenic transformation of neural stem cells and for the survival of "cancer cells with neural stemness" in a p53-dependent manner. 15 Upregulation of SIRT1/PGC-1α is associated with increased chemoand radio-resistance of glioblastoma stem cell clones, 37 while the shRNA-induced knockdown of SIRT1 expression enhances the effectiveness of radiotherapy by inhibiting tumor growth in CD133+ GBM xenografts in mice. 38 SIRT1 suppression by miRA-320 results in inhibition of forkhead box protein M1 (FoxM1) and enhancement of radiosensitivity of U251 and U87 glioma cells in vitro. 39 Correspondingly, the upregulation of miR-181a promotes glioma temozolomide (TMZ) sensitivity. 40 Also, the downregulation of SIRT1 through upregulation of miR-34a, provoked the expression of senescence related genes p53, Cdkn1a, and Cdkn2c. Furthermore, induction of miR-34a and subsequent SIRT1 inhibition induced DNA damage, shortened telomere length and impaired telomerase activity, functions that could synergize with existing chemo-radiation therapies. 41 Given the results of these prior studies, SIRT1 has emerged as a promising therapeutic target to aid in treatment of numerous cancers including GBM.
Molecular imaging with PET/CT(MRI) is a promising approach for the non-invasive, repetitive, visualization of expression-activity of HDAC enzymes, including SIRT1. respectively. In the current study, we demonstrate the efficacy of PET/CT/MRI with 2-[ 18 F]BzAHA for imaging the expression-activity of SIRT1 and for non-invasive monitoring of EX-527 induced inhibition of SIRT1 activity in 9L intracerebral glioma models in rats. Intracerebral Tumor Implantation. 9L rat gliosarcoma cells were obtained from the American Tissue Culture Collection (ATCC, Manassas, VA) and propagated in tissue culture treated T75 flasks (Corning, Tewksbury, MA). The 9L cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. For intracerebral (i.c.) injection of tumor cells, the culture media was aspirated and cells were dislodged using 0.25% trypsin (Thermo Fisher, Waltham, MA). Trypsin was inactivated using culture medium containing 10% FBS (Hyclone, Logan, UT); then, the cell suspension was centrifuged to obtain a cell pellet, which was re-suspended in cell culture medium without serum to achieve a concentration of 1x10 5 cells in 10 μL. Cell suspensions were kept at 2-4°C in an ice bath for no longer than 30 min. Male Sprague Dawley rats (Envigo, Indianapolis, IN, 400-500g) were used to generate the 9L glioma model (N=12). The top of the anesthetized rat's head was shaved, fixed in a stereotaxic frame (Kopf-Tujunga, Germany), and the skull exposed via a midline incision. A burr hole was generated using a micro-drill with a 2.3 mm tip (CellPoint Scientific, Gaithersburg, MD). A short beveled 26-ga needle attached to the 50 μL Hamilton A c c e p t e d M a n u s c r i p t 7 syringe (Hamilton Company, Reno, NV) containing tumor cell suspension, was inserted into the brain -1.5 AP, -4 mm LAT, -6 mm DV relative to bregma. The tumor cell suspension was slowly injected into the brain parenchyma over the period of 10 minutes to ensure steady resorption of injectate by the brain and to prevent the back-flux of cells into the subarachnoid and subdural spaces. After the needle was withdrawn, the hole in the dura was closed by cauterization, the burr hole filled with bone wax (Medline, Northfield, Il), and the skin incision closed using 3-0 black silk running suture (Ethicon, Somerville, NJ). The rats were monitored post-operatively for signs of distress, weight loss, or neurological deficit, and administered fluids (i.e., saline by subcutaneous injection) or nutritional supplements, as needed.
Materials and Methods

In vivo
MR imaging. T2-weighted MRI was performed two weeks following allograft implantation.
The animals were anesthetized by inhalation of isoflurane (5% in oxygen for induction, and 2-2.5% for maintenance). During the imaging procedure, the animals were placed on a heated re-circulating water platform in order to maintain body temperature at 37 o C. The animals were held in position using a bite bar and a home-built receive-only surface coil 2element phased array was placed dorsal to the head, as described elsewhere. 48 The SUV is defined as the ratio of the tissue radioactivity concentration (expressed as µCi/g tissue) at a given time point post injection, and the injected dose (in µCi, decay-corrected to the same time), and normalized by the body weight in grams. To obtain the ROI for the tumors on PET we used the MRI co-registration to identify the bulk of the tumor on PET.
After identifying the bulk of the tumor on PET, the tumor area was outlined as an ROI and Histology and immunofluorescence microscopy. Immediately following an imaging session, rats (N=6) were anesthetized using sodium pentobarbital (50 mg/kg) and transcardially perfused with 4% formaldehyde in phosphate buffer. After fixation in 4% formaldehyde and 30% sucrose, coronal brain sections (20µm) were obtained using (Fig. 1A; N=6) .
The maximum contrast between tumors versus brainstem and cortex was observed at 15-20 minutes post i.v. administration of 2-[ 18 F]BzAHA, resulting in SUVs of 1.11±0.058 (Fig. 1B) , and tumor-to-brainstem SUV ratios of 2.73±0.141 (Fig. 1C) for 9L gliomas. Also, increased levels of retention of 2-[ 18 F]BzAHA-derived radioactivity were observed in normal structures of the brain that are known to express higher levels of SIRT1, including hippocampus and n.
accumbens. Similar magnitudes of 2-[ 18 F]BzAHA time-activity curves (TACs) were observed during the first few minutes after intravenous administration in normal brain structures expressing high levels of SIRT1 (i.e., n. accumbens and hippocampus) and the magnitudes of TACs observed in 9L gliomas (Fig. S1 ).
Histological and immunofluorescence analyses of 9L brain tissue sections. To validate the results of non-invasive PET/CT/MRI of SIRT1 expression-activity and to determine which tumor regions contributed to increased 2-[ 18 F]BzAHA uptake, 3 animals bearing 9L tumors underwent perfusion fixation immediately after the imaging session. Their brains were extracted for histologic analyses. H&E staining of brain tissue sections confirmed the localization of tumors observed on MRI and PET images ( Fig. 2A-C) . Immunofluorescence staining in 9L tumors for SIRT1 demonstrated that the enzyme is overexpressed in the tumor parenchyma in a heterogenous pattern. Histopathological features typical to gliomas display increased SIRT1 immunofluorescence, particularly in hypoxic areas (i.e. regions of microvessel proliferation, pseudopalisades, and peri-necrotic areas). Glioma cells surrounding cavernous vessels ( Fig. 2D-F, top row) as well as in peri-necrotic glioma regions ( Fig. 2D-F, second 
row) observed on H&E show higher SIRT1 expression, as
A c c e p t e d M a n u s c r i p t 12 compared to non-hypoxic or less hypoxic-appearing surrounding tumor regions. In particular, the upregulation of SIRT1 expression was observed in pseudopalisading zones ( Fig. 2D-F,   third row) . Also, multiple foci of SIRT1 expression are dispersed throughout the tumor parenchyma ( Fig. 2D-F, bottom row) . (Figs. 3, S3 ). A c c e p t e d M a n u s c r i p t 14 compared to gliomas expressing lower levels of SIRT1. 60, 61 In contrast, other studies report reduced levels of SIRT1 expression in gliomas, 62 that 80% of GBM tumors exhibit a loss of one allele of the gene encoding SIRT1, 63 and that decreased levels of SIRT1 (both mRNA and protein) are predictive of poor prognosis, as compared to GBMs with diploid SIRT1, expressing higher levels of SIRT1. Potential reasons to this controversy may be partly due to spatial heterogeneity of gliomas (especially GBM) and variability of biopsy sites and tissue sampling during neurosurgical resection of gliomas in different clinical studies (i.e., from the infiltrating edge versus hypoxic and/or necrotic core). This controversy may have developed because quantitative measurements of SIRT1 mRNA expression levels do not necessarily reflect the levels of SIRT1 protein expression, which is dependent not only on transcriptional regulation, but mostly on post-transcriptional (i.e., different miRs). Also, the levels of total Pretreatment of 9L tumor-bearing rats with EX-527 at this dose did not significantly reduce the magnitude of SIRT1 expression-activity in the contralateral brain structures (i.e., n.accumbens, hippocampus), that are known to overexpress SIRT1. 46,67-70 Such differences in the magnitude of SIRT1 inhibition in 9L gliomas versus contralateral brain structures can be explained, at least in part, by higher concentrations of EX-527 delivered to the 9L tumor tissue through the leaky tumor microvasculature, as compared to relatively lower concentrations of EX-527 delivered in the contralateral brain structures with intact bloodbrain-barrier (BBB). Considering the mechanism of action of EX-527, it is unlikely that pretreatment with EX-527 by i.p. route 30 min prior to injection of 2- and other SIRT1-specific inhibitors or activators in gliomas and different structures of the brain, as reported by us previously for monitoring SAHA-induced inhibition of HDACs class IIa in the primate brain using PET/CT(MRI) with [ 18 F]TFAHA. 42 The observed inhibition of SIRT1 expression-activity in 9L tumors by EX-527 was isoform-selective, as evidenced by the lack of SIRT1 inhibition by pre-treatment with MC1568, which is the HDACs class IIa selective inhibitor. 71 These findings extend our initial studies in the normal rat brain using PET/CT(MRI) with 2-[ 18 F]BzAHA for monitoring the EX-527-induced pharmacologic inhibition of SIRT1 expression-activity in normal brain structures known to overexpress SIRT1 (i.e., hippocampus, amygdala, arcuate nucleus, n.accumbens). 46 Also, these findings are consistent with results of our studies using PET/CT(MRI) with [ 18 F]TFAHA that demonstrated effective inhibition of HDACs class IIa expression-activity in intracerebral 9L tumors by MC1568, and the lack of inhibition of HDACs class IIa expression-activity by EX-527. 45 It is well established that the levels many tumor-suppressor microRNA (miR) are downregulated in gliomas, leading to aberrant gene expression and glioma progression. 72 Administration of exogenous miR has been tested for treatment of gliomas, including miR-22, miR-34a, miR-132, miR-133b, mir-181a, miR-200a, miR-217, miR-320, and miR-3908. [73] [74] [75] [76] [77] [78] [79] [80] The MRX34 (miR-34a mimic) has been tested in a phase I multicenter clinical trial (NCT01829971) for the treatment of advanced solid tumors and demonstrated evidence of antitumor activity in a subset of patients. 81 PET/CT(MRI) with 2-[ 18 F]BzAHA could be potentially utilized for selection of glioma patients with high levels of SIRT1 expressionactivity levels in tumor tissue that may benefit from SIRT1-targeted pharmacologic and genetic therapies, including miR mimics, for monitoring the pharmacodynamics and dosedependency of SIRT1 inhibition and prediction of treatment response. 
PET/CT/MR imaging with 2-[ 18 F]BzAHA for monitoring the pharmacologic inhibition of
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